Sigmapharm relaunches its generic Amiloride Hydrochloride Tablets, USP 5 mg, exclusively under its own label.
Ms. Mary E. Kohart, Esq., who had joined the company in October 2020 as its Vice President of the Legal Affairs Department, has now also become the General Counsel of Sigmapharm Laboratories. Effective today, Mary will be in charge of all legal matters of the company, including but not limited to Paragraph-IV patent challenges and commercial litigation, contractual matters and strategic negotiations. A short biographical note of Mary’s has now been posted in the MANAGEMENT section of our website.
Please note that all outside legal counsel, law firms, vendors, customers and other companies wishing to communicate with Sigmapharm Laboratories for any legal, litigation or contractual matters are now directed to contact only Ms. Mary Kohart at:
Mary E. Kohart, Esq.
General Counsel and Vice President, Legal Affairs
Sigmapharm Laboratories, LLC
3375 Progress Drive
Bensalem, PA 19020
Tel.: (215) 352-6649
- Sigmapharm receives FDA approval for generic Asenapine Sublingual Tablets, 5 mg and 10 mg, based on its ANDA No. 206107 containing a Paragraph IV certification.
- Sigmapharm launches its generic Asenapine Sublingual Tablets, 5 mg and 10 mg.
Sigmapharm relaunches its generic Protriptyline Hydrochloride Tablets, USP 5 mg and 10 mg, exclusively under its own label.
Sigmapharm relaunches its generic Griseofulvin Tablets, USP (microsize) 500 mg, exclusively under its own label.
Sigmapharm files an Abbreviated New Drug Application (ANDA No. 213896) which is designated by the FDA as a Competitive Generics Therapy (CGT) product.
Sigmapharm launches its generic Ambrisentan Tablets, 5mg and 10mg.
Dr. Spireas, the Founder, Chairman and Chief Executive Officer of Sigmapharm Laboratories, received today (May 14, 2019) an Honorary Doctor of Science (D.Sc.) degree from Long Island University, Brooklyn, New York.
Sigmapharm receives FDA approval for generic Ambrisentan Tablets, 5 mg and 10 mg, based on its ANDA No. 208354 containing a Paragraph IV certification.